Page last updated: 2024-11-04

sevoflurane and Malignant Carcinoid Syndrome

sevoflurane has been researched along with Malignant Carcinoid Syndrome in 1 studies

Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.
sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.

Malignant Carcinoid Syndrome: A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Farling, PA1
Durairaju, AK1

Other Studies

1 other study available for sevoflurane and Malignant Carcinoid Syndrome

ArticleYear
Remifentanil and anaesthesia for carcinoid syndrome.
    British journal of anaesthesia, 2004, Volume: 92, Issue:6

    Topics: Aged; Analgesics, Opioid; Anesthesia, Epidural; Anesthesia, General; Anesthetics, Combined; Anesthet

2004